BioWorld

July 26, 2004

Aranesp, Enbrel, Neulasta Sales Drive Amgen To Beat Estimates

Amgen Inc. turned in second-quarter adjusted earnings per share of 62 cents, topping consensus estimates and surging 27 percent higher than a year ago. (BioWorld Today) Read More

Gene Logic Acquires Discovery Program, Team From Millennium

Specialty Pharma Firm Auxilium Raises $41.25M In Initial Offering

Santarus Gets $57M In Follow-On Following Approval Of Rapinex

Hudson Health Gains Listing Via Reverse Merger, Raises $8M

Tapestry Calls On Supratek To Help Develop New Formulations

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for Jan 12, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Jan. 12, 2026.

3D rendering of antibody drug conjugated with cytotoxic payload

ADCs’ breakout 2025 and their still-unfinished potential

BioWorld

Over the course of the year, and continuing into the latest scientific meetings, an extraordinary breadth of new antibody-drug conjugate (ADC) designs was...

Science in 2025: the best of the rest

BioWorld Science

A review of 2025's noteworthy advances in medical research, including GLP-1 receptor agonists as anti-aging drugs, tumor-agnostic therapies and xenotransplants.

LINC01116 has prognostic value in lung cancer, study shows

BioWorld MedTech

Long noncoding RNAs (lncRNAs) have emerged as potential markers of disease, since they associate with proteins that regulate gene expression, translation or...